Search
Economist Impact Report: Rethinking Mental Health Care
Partnering-Mental-Health-Disorders.pdf
Partnering-Outlook-Animal-Health-2024-USA.pdf
Prescription digital therapeutics and mental health care
Partnering-Animal-Health.pdf
Partnering-Retinal-Health.pdf
Public Health Cost from AF.pdf
Access to Healthcare Strategy PDF
Meet our Team
Meet Our Team
Our Culture of Caring: Volunteering
At BI we are committed to improving the health and well-being of people & animals. We encourage & support employee volunteer activities.
Boehringer Ingelheim and King’s College London join forces to progress new therapeutic concepts in major depressive disorder and schizophrenia
Boehringer Ingelheim and King’s College London join forces to progress new therapeutic concepts in major depressive disorder and schizophrenia
U.S. FDA Grants Breakthrough Therapy Designation for Spesolimab for the Prevention of Flares in Adults with Generalized Pustular Psoriasis (GPP)
U.S. FDA Grants Breakthrough Therapy Designation for Spesolimab for the Prevention of Flares in Adults with Generalized Pustular Psoriasis (GPP)
Boehringer Ingelheim and the Lieber Institute for Brain Development To Collaborate to Develop Centrally Acting COMT Inhibitors For the Treatment of Neuropsychiatric Disorders
Boehringer Ingelheim and the Lieber Institute for Brain Development To Collaborate to Develop Centrally Acting COMT Inhibitors For the Treatment of Neuropsychiatric Disorders
Yamagata
With its location in the Yamagata prefecture (Higashine), this site focuses on the production & packaging of human pharmaceuticals for the Japanese market.
Borderline Personality Disorder
Borderline Personality Disorder
Depression
Depression
Schizophrenia
Schizophrenia
More Potential
More Potential
Fighting COVID-19 | COVID-19 | Boehringer Ingelheim US
Read more on how Boehringer Ingelheim's work in developing vaccinations for animals has led us to support the pharma industry with the COVID-19 pandemic.
COVID-19: Boehringer Ingelheim steps up effort with Global Support Program
COVID-19: Boehringer Ingelheim steps up effort with Global Support Program
A Planned Safety Net for Patients in Need
A Planned Safety Net for Patients in Need
Swine
Swine
Partnering
Partnering
Efficacy and safety maintained in patients who switched from Humira® to biosimilar Cyltezo®
Efficacy and safety maintained in patients who switched from Humira® to biosimilar Cyltezo®